Anthropic just bought a biotech company. China's robots are doing factory internships. And your friends are injecting peptides.

Anthropic acquired Coefficient Bio, a stealth-mode biotech AI startup, in a $400 million stock deal. The company was building AI tools for biological research and drug discovery — and Anthropic just absorbed it entirely.

This isn't a talent acqui-hire. This is Anthropic saying: Claude isn't just for code and conversation. It's for biology. Drug discovery, genetic research, protein modeling — the kind of problems where the compute advantage of frontier AI could compress decades of research into years.

The deal was done in stock, not cash, which tells you Anthropic sees this as a long-term strategic play, not an expense. They're betting that the same architecture that makes Claude good at reasoning through complex code will make it good at reasoning through complex biology.

At Dongfeng Liuzhou Motor in Guangxi, China, eleven UBTech Walker S1 humanoid robots are working shifts on the factory floor — sorting parts, moving bins, collecting containers. They navigate using visual systems and follow instructor guidance to reach designated workstations. They're calling them 'interns.'

But this isn't just one factory. Approximately 120 humanoid robots are simultaneously training across a dedicated embodied AI data collection center in Liuzhou. The facility replicates production environments across automotive, construction equipment, pharmaceuticals, and food production.

The precision challenges are real — robots repeatedly practice picking up screws smaller than a fingernail using two fingers. Unlike humans who rely on instinct, every motion has to be algorithmically refined. UBTech partnered with Siemens to scale production, targeting 10,000 units annually. A separate facility by Leju Robotics is already completing a new robot every 30 minutes.

ARK's latest research reframes Bitcoin from speculation to portfolio infrastructure. Their thesis: Bitcoin is a scarce, non-sovereign asset in an era of government deficits, trade wars, and evolving monetary policy. It's a high-beta extension of gold with low correlation to other assets.

The data backs it up. In 2025, US spot Bitcoin ETFs and digital asset treasuries absorbed 1.2x the amount of newly mined Bitcoin plus dormant coins re-entering circulation. By year-end, ETFs and DATs held over 12% of total Bitcoin outstanding. The supply squeeze is structural, not speculative.

ARK's price targets: $300,000 to $1.5 million per Bitcoin by 2030, driven by institutional allocation that's still in its early innings. Volatility and drawdowns have decreased over a full market cycle, making the risk-adjusted case for portfolio inclusion stronger than ever.

The New Yorker published a deep dive on the exploding peptide underground. Millions of Americans are self-injecting compounds like BPC-157, GHK-Cu, and various growth hormone secretagogues for muscle building, skin rejuvenation, injury recovery, and longevity. Most aren't FDA-approved for human use. Many are purchased from overseas research chemical sites.

The scale is alarming. Peptide use is rampant among tech workers, gym culture, and even students at elite prep schools. When startup Finnrick tested commercially available peptides, 30% were mislabeled, under-dosed, over-dosed, or contaminated with toxins and bacteria.

RFK Jr. has vowed to end what he calls the 'FDA's war on peptides,' aligning with the Make America Healthy Again movement. The regulatory landscape is shifting — but the science hasn't caught up. Most evidence for these compounds comes from rat studies, not human clinical trials.

The Treasury Department designated BNY Mellon as the financial agent and Robinhood as the brokerage to run 'Trump Accounts' — government-backed investment accounts that give every child born between 2025 and 2028 a $1,000 deposit invested in broad U.S. stock index funds. An estimated 25 million families are eligible.

The rules are specific: money must go into low-cost index funds tracking the overall U.S. market — think S&P 500. No individual stocks, no sector bets, no leverage. Maximum 0.10% annual fees. If left untouched and fully funded, the Treasury estimates an account could grow to $1.9 million by age 28.

BNY and Robinhood are building a custom white-label app exclusively for Treasury. This isn't Robinhood's trading platform — it's a government savings product with Robinhood's UI. The program effectively creates millions of new passive index fund investors before they can walk.